Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2026 · 10-Q
Revenue$19.84M$19.84M−9.5% vs Q1 2025 Net Income-$495.00K-$495.00KN/M vs Q1 2025 EPS Diluted-$0.03-$0.03N/M vs Q1 2025 Operating Income$396,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Free Cash Flowderived-$488,000N/M Margins · derivedOperating margin2.0%+11.6 pt vs Q1 2025
Net margin-2.5%+7.5 pt vs Q1 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end